Pediatric skin cancer is rare but devastating, and standard cancer therapies are associated with both short- and long-term consequences. PeDRA’s STARC Focused Study Group works tirelessly to refine our understanding of primary skin tumors, to generate longitudinal data on the natural history and outcomes of potential precursors of skin malignancy, and to define and address unmet needs in cutaneous complications from therapies.
The STARC Focused Study Group is chaired by Carrie Coughlin, MD of Washington University. Contact us if you’re interested in getting involved!
Studies
Resources
View STARC specific funding, meeting, and journal resources:
Publications
Zhong, Connie, et al. “Characteristics of non-melanoma skin cancer in children without identifiable risk factors” Journal of the American Academy of Dermatology (2020).
Boull, Christina, et al. “Cutaneous Reactions in Children Treated with MEK Inhibitors, BRAF Inhibitors, or Combination Therapy: A Multi-Center Study” Journal of the American Academy of Dermatology (2020).
Hawryluk, Elena, et al. “A Retrospective Multicenter Study of Fatal Pediatric Melanoma” Journal of the American Academy of Dermatology (2020).
Akinshemoyin Vaughn, Olushola, et al. “Clinical and histologic presentation of pediatric reactive granulomatous dermatitis.” Pediatric Dermatology (2020).
Huang, Jennifer, et al. “Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults.” Journal of Pediatrics (2019).
Bartenstein, Diana W., et al. “Contrasting features of childhood and adolescent melanomas.” Pediatric Dermatology (2018).
“Pediatric Skin Cancer: Patient Perspectives.” Pediatric Dermatology (2017).